Skip to content
PubMed This is a summary of 5 peer-reviewed journal articles Updated
Medical Genetics · Hereditary Amyloidosis

Are V30M and p.Val50Met the Same Genetic Mutation?

At a Glance

V30M and p.Val50Met are the exact same genetic mutation that causes hereditary amyloidosis. The names differ only because modern labs count 20 extra amino acids at the start of the protein. You can safely use V30M resources to understand a p.Val50Met lab result, as the medical care is identical.

Yes, V30M and p.Val50Met are the exact same genetic mutation [1]. If your genetic report says you have the p.Val50Met mutation, you have what the amyloidosis community traditionally calls V30M [2]. The difference is simply in how scientists and genetic laboratories count the building blocks (amino acids) of the protein [3].

Why Are There Two Different Names?

The transthyretin (TTR) protein is made up of a chain of amino acids. To pinpoint exactly where a mutation occurs, scientists number these amino acids in order.

  • V30M (The Historical Name): In the past, scientists started counting amino acids beginning with the “mature” part of the protein that circulates in the blood [4]. When counted this way, the mutation occurs at position 30, where the amino acid valine (V) is replaced by methionine (M) [5]. This is why the variant has historically been called V30M.
  • p.Val50Met (The Standardized Name): Today, genetic testing labs use a strict international standard for naming mutations, known as HGVS nomenclature [3]. This modern standard requires counting from the very beginning of the protein, including a 20-amino-acid “signal peptide” (a temporary sequence that helps guide the protein in the cell before being removed) [4]. Because they include these 20 extra amino acids at the start, position 30 becomes position 50 (30 + 20 = 50) [5]. The “p.” simply stands for “protein,” while “Val” and “Met” are the three-letter abbreviations for valine and methionine.

Note: This +20 naming rule applies to all TTR mutations. For example, the variant traditionally called V122I will appear on modern lab reports as p.Val142Ile.

What This Means For You

Because V30M was discovered decades ago, almost all older research, support groups, and patient communities use the name V30M [5]. However, official laboratory reports and newer medical records use p.Val50Met to ensure accuracy and consistency across all genetic testing [3].

Rest assured, whether your doctor calls it V30M or your lab report reads p.Val50Met, they are talking about the exact same genetic variant, and the exact same medical care and treatment options apply [2]. You can safely use the wealth of information available on V30M to understand your p.Val50Met test result [1].

Search Tip: When looking for research, clinical trials, or patient support online, try using both “V30M” and “p.Val50Met” as search terms to ensure you find all available resources.

Common questions in this guide

Are V30M and p.Val50Met the same genetic mutation?
Yes, V30M and p.Val50Met are the exact same mutation in the transthyretin (TTR) gene. They just represent two different ways geneticists count the amino acid building blocks that make up the protein.
Why does my genetic report say p.Val50Met instead of V30M?
Modern genetic testing laboratories use a standardized naming system that includes 20 temporary amino acids at the beginning of the protein sequence. Because of this extra count, position 30 from the historical name (V30M) shifts to position 50 (p.Val50Met) on modern lab reports.
Does having p.Val50Met change my amyloidosis treatment options?
No, your care will not change. Because V30M and p.Val50Met are the exact same variant, the medical care and treatment options are identical. Your doctors will use established research on V30M amyloidosis to guide your treatment plan.
Should my family members be tested if I have the p.Val50Met mutation?
Because p.Val50Met is a hereditary mutation, your biological family members may also carry it. You should discuss with your doctor or genetic counselor how and when your relatives should consider genetic testing.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since my report shows the p.Val50Met variant, can you confirm that my care plan is based on the established research for V30M amyloidosis?
  2. 2.Does my current clinical team have experience treating patients specifically with the V30M/p.Val50Met mutation?
  3. 3.Knowing that I carry the p.Val50Met mutation, how and when should my biological family members consider being tested?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (5)
  1. 1

    New Medications in the Treatment of Hereditary Transthyretin Amyloidosis.

    Walker S

    Hospital pharmacy 2018; (53(4)):236-238 doi:10.1177/0018578718779757.

    PMID: 30038442
  2. 2

    Hereditary transthyretin amyloidosis with hand weakness and bulbar involvement.

    Bernsen S, Weydt P

    Practical neurology 2026; doi:10.1136/pn-2025-004950.

    PMID: 41482475
  3. 3

    Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.

    Sekijima Y, Ueda M, Koike H, et al.

    Orphanet journal of rare diseases 2018; (13(1)):6 doi:10.1186/s13023-017-0726-x.

    PMID: 29343286
  4. 4

    Large normal alleles of ATXN2 decrease age at onset in transthyretin familial amyloid polyneuropathy Val30Met patients.

    Santos D, Coelho T, Alves-Ferreira M, et al.

    Annals of neurology 2019; (85(2)):251-258 doi:10.1002/ana.25409.

    PMID: 30615214
  5. 5

    Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area.

    Wang S, Sun J, Lu Q, et al.

    International medical case reports journal 2022; (15()):299-306 doi:10.2147/IMCRJ.S357236.

    PMID: 35734096

This page explains genetic testing nomenclature for educational purposes only and does not replace professional medical advice. Always consult a genetic counselor or doctor to interpret your specific genetic testing results.

Get notified when new evidence is published on ATTRV30M amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.